Evolving trends in Breast Cancer Management

Dear Dr. Renukaprasad A R, Recent advances in breast cancer research have led to early diagnosis using various new radiological technologies, targeted systemic therapy, and precise radiotherapy planning and delivery. In addition, breast cancer surgery combines oncological principles with plastic surgical techniques to improve aesthetics with conservation surgeries.   Join the eminent breast oncosurgeon Dr. Chaitanyanand Koppiker in an exclusive Docplexus Surgical Suite session, where he will discuss "Oncoplasty: A Paradigm Shift in Breast Cancer Surgical Management" TODAY, 5:00 PM IST onwards. Session highlights - Evolving trends in the surgical management of breast cancer Omission of postoperative radiation post-conservation surgery Dealing with metastatic breast cancer Eliminating breast cancer surgery post neoadjuvant systemic therapy Join the Session Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

India: 85% of Surveyed Doctors Found to Be Obese, and More

Dear Dr. Renukaprasad A R, Top Stories of the Day: India: 85% of Surveyed Doctors Found to Be Obese India: DCGI Approves Covovax as a Heterologous Booster for Adults Study: 5% of Drugs Substandard TAWS-16: First-of-its-kind Tool to Measure Work Stress Webinar: Oncoplasty - A Paradigm Shift in Breast Cancer Surgical Management Healthcare headlines that matter, brought to you every day by Docplexus Health Minute! Watch News Docplexus is one of the world's largest online communities Pune - 411045, India Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Join the "Treating NSCLC with Ramucirumab" Session

Dear Dr. Renukaprasad A R, Ramucirumab is a successful second-line treatment option for patients with stage IV non-small cell lung cancer. These results from the REVEL study appear to be promising for managing the advanced stages of NSCLC. Join us TODAY from 07:30 PM to 08:30 PM IST to get deeper insights into the role of ramucirumab! We look forward to your active participation in this information-packed discussion! Highlights: Welcome and introduction Optimal management in EGFR-M+ NSCLC (Relaying RELAY + clinical case discussion) by Dr. Ashish Kaushal 2nd line NSCLC landscape updates for Cyramza® (REVEL + clinical case discussion) by Dr. Ghanashyam Biswas Summary and key takeaways Join the Session Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Lipid-based Artificial Tears: A Unique Solution for DED

Dear Dr. Renukaprasad A R, Do you know how lipid-containing eye drops improve lipid layer thickness in dry eye patients? Sometimes it is challenging to evaluate whether the underlying cause of dry eye disease (DED) is due to an aqueous or lipid deficiency. The tear film lipid layer plays a critical role in stabilizing and reducing tear film evaporation. Eye care practitioners can recommend proper eye drop formulations and dosing patterns to successfully target aqueous-deficient and evaporative types of DED as its prevalence continues to increase. Read this article to learn more about how nanoemulsion eye drops can improve DED symptoms and patients' quality of life. Highlights: Tear film lipid layer insufficiency and DED Why are nanoemulsion eye drops needed in DED treatment? Clinical evidence of nanoemulsion eye drops in DED Read More Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

NT-ProBNP: Biomarker for Heart Failure Management at Every Stage

Dear Dr. Renukaprasad A R, About 1% of the Indian population suffers from heart failure (HF), with an estimated mortality of 0.1-0.16 million individuals annually. It is estimated that up to 46% of type 2 diabetes mellitus patients will develop some form of CVD during their lifetime. ELECSYS NTproBNP is recognized as a gold standard biomarker in HF and is recommended by international HF guidelines. Serial NTproBNP measurements provide prognostic information on mortality and hospitalization for HF. Read this article to understand the application of NTproBNP for cardiac risk assessment in T2DM patients. Read More Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

The Know-how of Phacoemulsification

Dear Dr. Renukaprasad A R, A multidisciplinary, coordinated effort is vital for an ideal outcome after phacoemulsification, which includes the crucial role of surgeons, the nursing team, and the pharmacist. In addition, having sound knowledge of the best possible techniques to deal with intraoperative and postoperative challenges helps achieve a perfect visual outcome.  Join the eminent ophthalmologist, Dr. Suresh Pandey, in an exclusive session on "Phacoemulsification in Difficult Challenging Situations," TODAY, 3:00 PM IST onwards. Session highlights - Phacoemulsification in compromised rhexis Management of polar cataracts Dealing with subluxated lens Challenges in intraocular lens implantation Enhancing healthcare team outcomes Click to Join Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*